Among them, a phase I first-in-human trial tested BNT211, an autologous CAR-T cell therapy targeting the oncofetal antigen claudin-6 (CLDN6), and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac) in patients with CLDN6-positive relapsed/refractory non-hematological cancers, including 13 GCT patients [90]. This evidence concerns the gene CLDN6 and granular cell tumor.